Nilofer S. Azad

30.3k total citations · 3 hit papers
205 papers, 6.3k citations indexed

About

Nilofer S. Azad is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Nilofer S. Azad has authored 205 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Oncology, 52 papers in Molecular Biology and 50 papers in Surgery. Recurrent topics in Nilofer S. Azad's work include Pancreatic and Hepatic Oncology Research (41 papers), Cancer Genomics and Diagnostics (40 papers) and Colorectal Cancer Treatments and Studies (40 papers). Nilofer S. Azad is often cited by papers focused on Pancreatic and Hepatic Oncology Research (41 papers), Cancer Genomics and Diagnostics (40 papers) and Colorectal Cancer Treatments and Studies (40 papers). Nilofer S. Azad collaborates with scholars based in United States, Canada and Netherlands. Nilofer S. Azad's co-authors include Elizabeth M. Jaffee, Stephen B. Baylin, Daniel A. Laheru, Cynthia A. Zahnow, Mark Yarchoan, Elise C. Kohn, Charles M. Rudin, Luis A. Díaz, Christina M. Annunziata and Eric S. Christenson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Nilofer S. Azad

193 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

2019 386 citations Mark Yarchoan, Lee A. Albacker et al. JCI Insight profile →
PD-1 blockade in tumors with mismatch repair deficiency.

2015 339 citations Dung T. Le, Nilofer S. Azad et al. Journal of Clinical Oncology profile →
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

2021 251 citations Milind Javle, Mitesh J. Borad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nilofer S. Azad United States	41	3.8k	2.3k	1.4k	1.3k	1.1k	205	6.3k
Michael J. Pishvaian United States	40	3.8k 1.0×	1.9k 0.8×	1.1k 0.8×	1.5k 1.2×	747 0.7×	216	5.8k
Élena Elez Spain	38	4.5k 1.2×	1.7k 0.7×	1.4k 1.0×	1.2k 1.0×	951 0.8×	212	6.1k
Kyung-Hun Lee South Korea	35	4.1k 1.1×	1.6k 0.7×	2.0k 1.4×	1.5k 1.2×	706 0.6×	216	6.0k
Shivaani Kummar United States	47	3.5k 0.9×	3.3k 1.4×	1.5k 1.1×	1.3k 1.0×	378 0.3×	296	7.0k
Helen X. Chen United States	37	4.1k 1.1×	3.9k 1.7×	2.6k 1.9×	2.0k 1.6×	696 0.6×	84	8.9k
Geke A.P. Hospers Netherlands	45	3.9k 1.0×	2.1k 0.9×	1.5k 1.1×	1.1k 0.9×	1.7k 1.5×	282	7.4k
Vassilis Georgoulias Greece	48	4.9k 1.3×	2.8k 1.2×	2.7k 2.0×	2.4k 1.9×	610 0.5×	296	8.3k
Christophe Le Tourneau France	46	4.9k 1.3×	2.1k 0.9×	2.3k 1.7×	1.6k 1.3×	1.3k 1.2×	335	8.7k
Jennifer J. Wheler United States	42	2.6k 0.7×	3.2k 1.4×	1.8k 1.3×	2.1k 1.6×	418 0.4×	199	6.7k
Filippo Pietrantonio Italy	37	2.9k 0.8×	1.1k 0.5×	1.5k 1.1×	1.2k 1.0×	1.1k 1.0×	298	5.0k

Countries citing papers authored by Nilofer S. Azad

Since Specialization

Citations

This map shows the geographic impact of Nilofer S. Azad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nilofer S. Azad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nilofer S. Azad more than expected).

Fields of papers citing papers by Nilofer S. Azad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nilofer S. Azad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nilofer S. Azad. The network helps show where Nilofer S. Azad may publish in the future.

Co-authorship network of co-authors of Nilofer S. Azad

This figure shows the co-authorship network connecting the top 25 collaborators of Nilofer S. Azad. A scholar is included among the top collaborators of Nilofer S. Azad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nilofer S. Azad. Nilofer S. Azad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Visvanathan, Kala, Deborah K. Armstrong, Jin He, et al.. (2025). Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. JCO Precision Oncology. 9(9). e2400494–e2400494. 1 indexed citations

Xiao, Lianchun, Mitesh J. Borad, Robin Kate Kelley, et al.. (2025). Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials. Cancer. 132(1). e70227–e70227.

Heumann, Thatcher, Mark Yarchoan, Jiayun Lu, et al.. (2024). A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). 4017–4017. 3 indexed citations

Lee, Valerie, Rose Parkinson, Marianna Zahurak, et al.. (2024). A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal of Cancer. 154(10). 1794–1801. 7 indexed citations

Kessler, Michael D., Xiaoshan M. Shao, Archana Balan, et al.. (2024). SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors. Cancer Research Communications. 4(12). 3137–3150. 2 indexed citations

Baretti, Marina, Adrian Murphy, Marianna Zahurak, et al.. (2023). A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics. 15(1). 74–74. 12 indexed citations

Paller, Channing J., Lin Wang, Wei Fu, et al.. (2023). Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer Research Communications. 3(2). 338–346. 7 indexed citations

Durham, Jennifer N., Su Jin Lim, Katherine M. Bever, et al.. (2023). Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Cancer Research Communications. 3(8). 1672–1677. 5 indexed citations

Yarchoan, Mark, Subir Goyal, Yuan Liu, et al.. (2022). Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research. 28(19). 4336–4345. 10 indexed citations

10.

Dennison, Lauren, Aditya Mohan, James M. Leatherman, et al.. (2021). Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. 9(10). 1187–1201. 17 indexed citations

11.

Baretti, Marina, Enusha Karunasena, Marianna Zahurak, et al.. (2021). A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science. 14(3). 954–963. 7 indexed citations

12.

Douma, Joeri A J, Laurien M. Buffart, Ramy Sedhom, et al.. (2021). Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. Cancers. 13(10). 2304–2304. 4 indexed citations

13.

Osipov, Arsen, Su Jin Lim, Aleksandra Popović, et al.. (2020). Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. Clinical Cancer Research. 26(18). 4842–4851. 69 indexed citations

14.

Ferrell, Betty, Vincent Chung, Mark T. Hughes, et al.. (2020). A Palliative Care Intervention for Patients on Phase 1 Studies. Journal of Palliative Medicine. 24(6). 846–856. 29 indexed citations

15.

Kurzrock, Razelle, Douglas W. Ball, Marianna Zahurak, et al.. (2019). A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research. 25(18). 5475–5484. 19 indexed citations

16.

Danilova, Ludmila, Won Jin Ho, Qingfeng Zhu, et al.. (2019). Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunology Research. 7(6). 886–895. 180 indexed citations

17.

Yarchoan, Mark, Lee A. Albacker, Alexander C. Hopkins, et al.. (2019). PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 4(6). 386 indexed citations breakdown →

18.

Yarchoan, Mark, Chiung‐Yu Huang, Qingfeng Zhu, et al.. (2019). A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Medicine. 9(4). 1485–1494. 68 indexed citations

19.

Hu, Chaoxin, Venugopal Chenna, Shinichi Yabuuchi, et al.. (2015). Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics. 14(7). 1532–1539. 60 indexed citations

20.

Reiss, Kim A., Joseph M. Herman, Marianna Zahurak, et al.. (2014). A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. Clinical Cancer Research. 21(1). 68–76. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact